Last updated: 2026-09-07 21:17:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cyclerion Therapeutics, Inc. (CYCN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.24, with a market capitalization of $19.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.03 to $8.48. This page covers its latest market performance, valuation, price trends and company information.
$19.90M | |
$4.53 | |
$420.00 | |
$1.03 | |
$4.96 | |
96.48K | |
39.57K | |
-- | |
$8.48 | |
$1.03 | |
-- | |
-- |
Cyclerion Therapeutics, Inc. (CYCN) last closed at $4.96 as of 2026-09-04 23:31:00, unchanged from the previous close of $4.96.
During the latest regular trading session, CYCN traded between $1.03 and $420.00, with a volume of 96.48K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Cyclerion Therapeutics, Inc. (CYCN) moved from $3.99 to $4.24, representing a gain of 6.37% ($0.25).
The stock traded between $3.55 and $5.19 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 116.47 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 43.2%
CYCN is currently trading at $4.24, placing it 43.2% of the way from its 52-week low of $1.03 to its 52-week high of $8.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cyclerion Therapeutics, Inc. (CYCN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.